Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Average (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Equity Average for 6 consecutive years, with $50.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 39.17% year-over-year to $50.2 million, compared with a TTM value of $50.2 million through Sep 2025, down 39.17%, and an annual FY2024 reading of $78.0 million, down 29.1% over the prior year.
  • Equity Average was $50.2 million for Q3 2025 at Ovid Therapeutics, down from $57.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $213.9 million in Q2 2021 and bottomed at $50.2 million in Q3 2025.
  • Average Equity Average over 5 years is $120.4 million, with a median of $115.8 million recorded in 2023.
  • The sharpest move saw Equity Average surged 422.19% in 2021, then crashed 39.17% in 2025.
  • Year by year, Equity Average stood at $188.4 million in 2021, then fell by 27.19% to $137.2 million in 2022, then plummeted by 31.07% to $94.5 million in 2023, then fell by 23.57% to $72.3 million in 2024, then tumbled by 30.47% to $50.2 million in 2025.
  • Business Quant data shows Equity Average for OVID at $50.2 million in Q3 2025, $57.5 million in Q2 2025, and $63.8 million in Q1 2025.